Transcriptomic analysis reveals reduced transcriptional activity in the malaria parasite Plasmodium cynomolgi during progression into dormancy

Abstract

Relapses of Plasmodium dormant liver hypnozoites compromise malaria eradication efforts. New radical cure drugs are urgently needed, yet the vast gap in knowledge of hypnozoite biology impedes drug discovery. We previously unraveled the transcriptome of 6 to 7 day-old P. cynomolgi liver stages, highlighting pathways associated with hypnozoite dormancy (Voorberg-van der Wel, 2017). We now extend these findings by transcriptome profiling of 9 to 10 day-old liver stage parasites, thus revealing for the first time the maturation of the dormant stage over time. Although progression of dormancy leads to a 10-fold decrease in transcription and expression of only 840 genes, including genes associated with housekeeping functions, we show that pathways involved in quiescence, energy metabolism and maintenance of genome integrity remain the prevalent pathways active in mature hypnozoites.

Data availability

The raw RNA-sequencing reads are available in the NCBI Short Read Archive (https://www.ncbi.nlm.nih.gov/sra) under accession number SRP096160.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Nicole L Bertschi

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Nicole L Bertschi, employed by and/or shareholders of Novartis Pharma AG.
  2. Annemarie Voorberg-van der Wel

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9403-0515
  3. Anne-Marie Zeeman

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  4. Sven Schuierer

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Sven Schuierer, employed by and/or shareholders of Novartis Pharma AG.
  5. Florian Nigsch

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Florian Nigsch, employed by and/or shareholders of Novartis Pharma AG.
  6. Walter Carbone

    Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Walter Carbone, employed by and/or shareholders of Novartis Pharma AG.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6150-8295
  7. Judith Knehr

    Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Judith Knehr, employed by and/or shareholders of Novartis Pharma AG.
  8. Devendra Kumar Gupta

    Novartis Institute for Tropical Diseases, Emeryville, United States
    Competing interests
    Devendra Kumar Gupta, employed by and/or shareholders of Novartis Pharma AG.
  9. Sam O Hofman

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  10. Nicole van der Werff

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  11. Ivonne Nieuwenhuis

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  12. Els Klooster

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  13. Bart W Faber

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    Competing interests
    No competing interests declared.
  14. Erika L Flannery

    Novartis Institute for Tropical Diseases, Emeryville, United States
    Competing interests
    Erika L Flannery, employed by and/or shareholders of Novartis Pharma AG.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0665-7954
  15. Sebastian Mikolajczak

    Novartis Institute for Tropical Diseases, Emeryville, United States
    Competing interests
    Sebastian Mikolajczak, employed by and/or shareholders of Novartis Pharma AG.
  16. Binesh Shrestha

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Binesh Shrestha, employed by and/or shareholders of Novartis Pharma AG.
  17. Martin Beibel

    Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Martin Beibel, employed by and/or shareholders of Novartis Pharma AG.
  18. Tewis Bouwmeester

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Competing interests
    Tewis Bouwmeester, employed by and/or shareholders of Novartis Pharma AG.
  19. Niwat Kangwanrangsan

    Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand
    Competing interests
    No competing interests declared.
  20. Jetsumon Sattabongkot

    Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3938-4588
  21. Thierry Tidiane Diagana

    Novartis Institute for Tropical Diseases, Emeryville, United States
    Competing interests
    Thierry Tidiane Diagana, employed by and/or shareholders of Novartis Pharma AG.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8520-5683
  22. Clemens H M Kocken

    Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands
    For correspondence
    kocken@bprc.nl
    Competing interests
    No competing interests declared.
  23. Guglielmo Roma

    Chemical Biology and Therapeutics, Novartis Institutes for BioMedical Research, Basel, Switzerland
    For correspondence
    guglielmo.roma@novartis.com
    Competing interests
    Guglielmo Roma, employed by and shareholders of Novartis Pharma AG.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8020-4219

Funding

Bill and Melinda Gates Foundation

  • Thierry Tidiane Diagana
  • Clemens H M Kocken
  • Guglielmo Roma

Wellcome

  • Thierry Tidiane Diagana
  • Clemens H M Kocken

Medicines for Malaria Venture

  • Thierry Tidiane Diagana
  • Clemens H M Kocken

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Nonhuman primates were used because no other models (in vitro or in vivo) were suitable for the aims of this project. The research protocol was approved by the local independent ethical committee conform Dutch law (BPRC Dier Experimenten Commissie, DEC, agreement number #708). Details are described by Voorberg-van der Wel [4].

Copyright

© 2018, Bertschi et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,369
    views
  • 452
    downloads
  • 40
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Nicole L Bertschi
  2. Annemarie Voorberg-van der Wel
  3. Anne-Marie Zeeman
  4. Sven Schuierer
  5. Florian Nigsch
  6. Walter Carbone
  7. Judith Knehr
  8. Devendra Kumar Gupta
  9. Sam O Hofman
  10. Nicole van der Werff
  11. Ivonne Nieuwenhuis
  12. Els Klooster
  13. Bart W Faber
  14. Erika L Flannery
  15. Sebastian Mikolajczak
  16. Binesh Shrestha
  17. Martin Beibel
  18. Tewis Bouwmeester
  19. Niwat Kangwanrangsan
  20. Jetsumon Sattabongkot
  21. Thierry Tidiane Diagana
  22. Clemens H M Kocken
  23. Guglielmo Roma
(2018)
Transcriptomic analysis reveals reduced transcriptional activity in the malaria parasite Plasmodium cynomolgi during progression into dormancy
eLife 7:e41081.
https://doi.org/10.7554/eLife.41081

Share this article

https://doi.org/10.7554/eLife.41081

Further reading

    1. Microbiology and Infectious Disease
    Brooke E White, Carolyn L Hodo ... Rick L Tarleton
    Research Article

    Infection with the protozoan parasite Trypanosoma cruzi is generally well-controlled by host immune responses, but appears to be rarely eliminated. The resulting persistent, low-level infection results in cumulative tissue damage with the greatest impact generally in the heart in the form of chagasic cardiomyopathy. The relative success in immune control of T. cruzi infection usually averts acute phase death but has the negative consequence that the low-level presence of T. cruzi in hosts is challenging to detect unequivocally. Thus, it is difficult to identify those who are actively infected and, as well, problematic to gauge the impact of treatment, particularly in the evaluation of the relative efficacy of new drugs. In this study, we employ DNA fragmentation and high numbers of replicate PCR reaction (‘deep-sampling’) and to extend the quantitative range of detecting T. cruzi in blood by at least three orders of magnitude relative to current protocols. When combined with sampling blood at multiple time points, deep sampling of fragmented DNA allowed for detection of T. cruzi in all infected hosts in multiple host species, including humans, macaques, and dogs. In addition, we provide evidence for a number of characteristics not previously rigorously quantified in the population of hosts with naturally acquired T. cruzi infection, including, a >6 log variation between chronically infected individuals in the stable parasite levels, a continuing decline in parasite load during the second and third years of infection in some hosts, and the potential for parasite load to change dramatically when health conditions change. Although requiring strict adherence to contamination–prevention protocols and significant resources, deep-sampling PCR provides an important new tool for assessing therapies and for addressing long-standing questions in T. cruzi infection and Chagas disease.

    1. Microbiology and Infectious Disease
    2. Neuroscience
    Aleksandra Prochera, Anoohya N Muppirala ... Meenakshi Rao
    Research Article

    Glial cells of the enteric nervous system (ENS) interact closely with the intestinal epithelium and secrete signals that influence epithelial cell proliferation and barrier formation in vitro. Whether these interactions are important in vivo, however, is unclear because previous studies reached conflicting conclusions (Prochera and Rao, 2023). To better define the roles of enteric glia in steady state regulation of the intestinal epithelium, we characterized the glia in closest proximity to epithelial cells and found that the majority express the gene Proteolipid protein 1 (PLP1) in both mice and humans. To test their functions using an unbiased approach, we genetically depleted PLP1+ cells in mice and transcriptionally profiled the small and large intestines. Surprisingly, glial loss had minimal effects on transcriptional programs and the few identified changes varied along the gastrointestinal tract. In the ileum, where enteric glia had been considered most essential for epithelial integrity, glial depletion did not drastically alter epithelial gene expression but caused a modest enrichment in signatures of Paneth cells, a secretory cell type important for innate immunity. In the absence of PLP1+ glia, Paneth cell number was intact, but a subset appeared abnormal with irregular and heterogenous cytoplasmic granules, suggesting a secretory deficit. Consistent with this possibility, ileal explants from glial-depleted mice secreted less functional lysozyme than controls with corresponding effects on fecal microbial composition. Collectively, these data suggest that enteric glia do not exert broad effects on the intestinal epithelium but have an essential role in regulating Paneth cell function and gut microbial ecology.